Literature DB >> 28401192

Evasion of targeted cancer therapy through stem-cell-like reprogramming.

Kristine M Wadosky1, Leigh Ellis2, David W Goodrich1.   

Abstract

Prostate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage plasticity, and antiandrogen resistance. Epigenetic manipulation restores antiandrogen sensitivity-suggesting an approach for treating lethal prostate cancers.

Entities:  

Keywords:  Epigenetic reprogramming; mouse models; prostate cancer; therapeutic resistance; tumor suppressor genes

Year:  2017        PMID： 28401192      PMCID： PMC5383359          DOI： 10.1080/23723556.2017.1291397

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Authors:  Sean R Williamson; Shaobo Zhang; Jorge L Yao; Jiaoti Huang; Antonio Lopez-Beltran; Steven Shen; Adeboye O Osunkoya; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

2.  Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.

Authors:  Stephen J Freedland; William J Aronson
Journal:  Urol Oncol       Date:  2017-06-13       Impact factor: 3.498

3.  A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Authors:  Bryan A Smith; Artem Sokolov; Vladislav Uzunangelov; Robert Baertsch; Yulia Newton; Kiley Graim; Colleen Mathis; Donghui Cheng; Joshua M Stuart; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

4.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

Authors:  Ping Mu; Zeda Zhang; Matteo Benelli; Wouter R Karthaus; Elizabeth Hoover; Chi-Chao Chen; John Wongvipat; Sheng-Yu Ku; Dong Gao; Zhen Cao; Neel Shah; Elizabeth J Adams; Wassim Abida; Philip A Watson; Davide Prandi; Chun-Hao Huang; Elisa de Stanchina; Scott W Lowe; Leigh Ellis; Himisha Beltran; Mark A Rubin; David W Goodrich; Francesca Demichelis; Charles L Sawyers
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

5.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Authors:  Sheng Yu Ku; Spencer Rosario; Yanqing Wang; Ping Mu; Mukund Seshadri; Zachary W Goodrich; Maxwell M Goodrich; David P Labbé; Eduardo Cortes Gomez; Jianmin Wang; Henry W Long; Bo Xu; Myles Brown; Massimo Loda; Charles L Sawyers; Leigh Ellis; David W Goodrich
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

Review 6.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.

Authors:  Philip A Watson; Vivek K Arora; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2015-11-13       Impact factor: 60.716

7.  The Molecular Taxonomy of Primary Prostate Cancer.

Authors: 
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

8.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

9.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Authors:  Matthew J Niederst; Lecia V Sequist; John T Poirier; Craig H Mermel; Elizabeth L Lockerman; Angel R Garcia; Ryohei Katayama; Carlotta Costa; Kenneth N Ross; Teresa Moran; Emily Howe; Linnea E Fulton; Hillary E Mulvey; Lindsay A Bernardo; Farhiya Mohamoud; Norikatsu Miyoshi; Paul A VanderLaan; Daniel B Costa; Pasi A Jänne; Darrell R Borger; Sridhar Ramaswamy; Toshi Shioda; Anthony J Iafrate; Gad Getz; Charles M Rudin; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Nat Commun       Date:  2015-03-11       Impact factor: 14.919

10.  Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.

Authors:  Dingxiao Zhang; Daechan Park; Yi Zhong; Yue Lu; Kiera Rycaj; Shuai Gong; Xin Chen; Xin Liu; Hsueh-Ping Chao; Pamela Whitney; Tammy Calhoun-Davis; Yoko Takata; Jianjun Shen; Vishwanath R Iyer; Dean G Tang
Journal:  Nat Commun       Date:  2016-02-29       Impact factor: 14.919
  10 in total
  3 in total

1.  BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2.

Authors:  Divya Bhagirath; Thao Ly Yang; Z Laura Tabatabai; Shahana Majid; Rajvir Dahiya; Yuichiro Tanaka; Sharanjot Saini
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

2.  The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.

Authors:  Harvey R Fernandez; Shreyas M Gadre; Mingjun Tan; Garrett T Graham; Rami Mosaoa; Martin S Ongkeko; Kyu Ah Kim; Rebecca B Riggins; Erika Parasido; Iacopo Petrini; Simone Pacini; Amrita Cheema; Rency Varghese; Habtom W Ressom; Yuwen Zhang; Christopher Albanese; Aykut Üren; Mikell Paige; Giuseppe Giaccone; Maria Laura Avantaggiati
Journal:  Cell Death Differ       Date:  2018-04-12       Impact factor: 15.828

3.  Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.

Authors:  Yi Ma; Lijie He; Qianwen Huang; Shuang Zheng; Zhiqiang Zhang; Hongshi Li; Shuang Liu
Journal:  BMC Med Genet       Date:  2018-10-17       Impact factor: 2.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.